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Binding of a specific peptide(s) from a viral protein to major histocompatibility complex (MHC) class I molecules is a critical
step in the activation of CD81 cytotoxic T lymphocytes (CTLs). Once activated, CTLs can cause lethal disease in an infected
host, for example, by killing virus-containing ependymal and ventricular cells in the central nervous system or viral
protein-expressing b cells in the pancreatic islets of Langerhans. Here we describe the usage of a designed (not natural)
high-affinity peptide to compete with viral peptide(s)–MHC binding. This peptide blocks virus-induced CTL-mediated disease
both in the CNS and in the pancreatic islets in vivo. Further, the blocking peptide aborts MHC-restricted killing of target cells
by CTLs generated to three separate viruses: lymphocytic choriomeningitis virus, influenza virus, and simian virus 40. © 1999
Academic Press
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GINTRODUCTION
In response to infection by a virus, the host generates
n antiviral immune response designed to attack that
irus as well as cells producing viral progeny. Immuno-
athologic injury is an expected complication of this
atural process, in some instances progressing to dis-
ase (reviewed in Whitton and Oldstone, 1996). This
cenario involves the production of viral proteins by
nfected cells and then degradation of those proteins into
mall peptide fragments, usually 8 to 12 amino acids (aa)
n length, which appear on the cell surface in association
ith major histocompatibility complex class I (MHC I)
lycoprotein (Zinkernagel and Doherty, 1974; Townsend
nd Bodmer, 1989). In turn, such peptide–MHC com-
lexes trigger cytotoxic T lymphocytes (CTLs) to destroy
he virally infected cells. Additionally, these CD81 T cells,
long with CD41 T cells, release cytokines that partici-
ate actively in the immune process. Further, antibodies
o the viruses form in the fluid phases to yield virus–
ntiviral antibody immune complexes (Oldstone, 1975).
he net result is a decrease of infectious particles by
eutralization, aggregation, or with complement directing
he complex to cells such as macrophages that possess
c receptors and actively degrade the immune complex.
owever, such complexes also deposit in renal glomer-
li and arteries to cause immune complex disease. Al-
hough both the humoral (antibody) and the cellular (T
1 To whom correspondence and reprint requests should be ad-
mressed.
042-6822/99 $30.00
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246ymphocyte) pathways play roles in infection, genetic,
linical, and basic research points to T lymphocytes as
he major player involved in the control of most viral
nfections (Whitton and Oldstone, 1996; Good, 1991; Old-
tone, 1997). With acute viral infections an imbalance of
he immune response and viral replication causes termi-
ation of disease (immunity), death of the host, or per-
istent infection.
Lymphocytic choriomeningitis virus (LCMV) infection
f its natural host, the mouse, has provided most of the
riginal data and concepts for virus-induced immunopa-
hology (reviewed in Buchmeier et al., 1980; Borrow and
ldstone, 1997). These include virus antigen–antibody
mmune complexes and T-cell-mediated injury, T cell
ecognition, and MHC restriction. Such phenomena
roved to be universal and apply in other viral and
icrobial infections.
LCMV is a negative-strand RNA virus with an am-
isense coding strategy (Bishop and Auperin, 1987;
outhern et al., 1987; Salvato et al., 1989). The viral
enome is segmented into two strands, a large (L) RNA
nd a small (S) RNA of 7.2 and 3.4 kb, respectively. The
RNA encodes from the 39 end a polymerase (L) protein
approximately 200 kDa) and from the 59 end a protein
alled Z (10 to 12 kDa) (Salvato et al., 1992). The S RNA
ncodes three structural proteins: from the 39 end, the
nternal nucleocapsid (NP; 63 kDa) and from the 59 end,
wo surface glycoproteins, GP1 (43 kDa) and GP2 (36
Da), derived from a common precursor polypeptide
PC (Riviere et al., 1985). Reassortment of RNA seg-
ents from different LCMV strains and using vaccinia
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247HIGH-AFFINITY PEPTIDE ABORTS MHC RESTRICTED CTL ACTIVITYirus (VV) recombinants to express GP, NP, or Z revealed
hat H-2b mice generate CTLs to the GP and NP proteins
ncoded by the S RNA (Riviere et al., 1986; Whitton et al.,
988). Using VV recombinants expressing a series of GP
nd NP deletions combined with overlapping synthe-
ized peptides revealed that for LCMV Armstrong (ARM)
train had two peptide sequences for GP, aa 33–41
AVYNFATC (GP1) and aa 276–286 SGVENPGGYCL
GP2), and one for NP, aa 396–404 FQPQNGQFI, that
erve as epitopes for CTL activation and recognition.
se of cells from recombinant inbred mouse strains
howed that these three major peptides were restricted
o the Db allele of H-2b. While the other MHC class I
llele, Kb, can also restrict a LCMV peptide GP aa 32–41
Hudrisier et al., 1997), it rarely does so unless the Db
ene is disrupted. Similarly, there are minor Db-restricted
eptide epitopes but these become functional primarily
hen all the Db major epitopes have mutated or during
epeated immunizations (Lewicki et al., 1995; van der
ost et al., 1998).
Because binding of viral peptides to MHC class I mole-
ules is a necessary and early step for CTL activation, we
nalyzed the anchor and flanking sequences of the LCMV
b-restricted peptides as well as Db-restricted peptides
rom influenza virus NP and simian virus 40 (SV40) T anti-
en (Hudrisier et al., 1996). The results enabled us to de-
ign and synthesize a high-affinity Db MHC antagonist pep-
ide that would block the activity of LCMV, influenza virus,
nd SV40 CTLs in vitro. This peptide was then tested in vivo
ith two separate models in an attempt to block immuno-
athologic disease caused by Db-restricted CTL. For the
irst model, we used previous results (Borrow and Oldstone,
997) showing that the consequence of injecting LCMV
ntracerebrally (ic 10 PFU) into immunocompetent adult
-2b mice was that CTLs specific for LCMV GP1, GP2, and
P formed and migrated to the brain, where they recog-
ized and killed ventricular and meningeal cells expressing
he LCMV peptide–MHC complex. For the second model,
ice manipulated with the rat insulin promoter (RIP) to
xpress LCMV GP in b cells of the pancreatic islets (Old-
tone et al., 1991; von Herrath et al., 1994a) then acutely
nfected with LCMV generated CTL that killed islet cells
xpressing GP1 and GP2 Db-restricted peptides leading to
iabetes. In both situations, administration of the Db block-
ng peptide prevented cell death and reduced the incidence
f disease. Thus, we successfully designed and imple-
ented an MHC-blocking peptide as therapy to prevent
TL-mediated injury in vivo and to a spectrum of different
iruses.
RESULTS
eptide binding studies and design of the antagonist
eptide
Peptides from a variety of RNA and DNA viruses are
nown to bind to the Db allele of MHC class I molecules nnd to activate their respective antiviral CTLs, resulting
n CTL-mediated lysis of H-2b targets (Hudrisier et al.,
996; Oldstone et al., 1991; von Herrath et al., 1994a,b;
ewicki et al., 1995a,b; Klavinskis et al., 1990; Oldstone et
l., 1988; Yanagi et al., 1992; Whitton et al., 1989; Vitiello
t al., 1990; Lippolis et al., 1995; Mylin et al., 1995). We
ynthesized Db binding peptides for LCMV, influenza
irus, and SV40 and also from the GP and NP of LCMV
RM that possess the consensus Db binding motif: aa 9,
0, 11, or 12 in length with asparagine (N) in position 5
nd a hydrophobic aa or methionine (M) at the COO2
esidue at position 9, 10, 11, or 12. Table 1 records the
inding of the peptides to Db and subsequent lysis of
eptide coated LCMV infected target cells. These results
upported our earlier observations (Hudrisier et al., 1996)
hat the binding of a peptide at high affinity (,100 nM at
0% inhibition of binding) required aa S, T, or C at posi-
ion (P) 1 and P2; V, L, I, or M at P3; D or E at P4 and P6;
nd Y, F, or W at P8. The use of alanine scan mutants and
ata from study of LCMV ARM H-2b escape CTL variants
Lewicki et al., 1995a) located residues that extended
pward to engage the CTL receptor at P3, 6, and 8. We
hen designed a nonviral peptide SMIENLEYM that
ould bind at high affinity to Db (14 6 2 nM, mean value
rom three independent studies 61 SE). However, when
sed to coat H-2b MC57 targets, this peptide was not
ecognized by Db-restricted CTL clones to LCMV, influ-
nza virus, or SV40.
MIENLEYM peptide effectively blocks specific H-2
Db)-restricted lysis by LCMV, influenza, and SV40
TL
We next determined whether the Db blocking peptide
MIENLEYM, which by itself was unable to sensitize
b-expressing cells for lysis by Db-restricted CTLs (Table
), could block specific CTL-mediated killing of H-2b (Db)
argets. For these studies, the SMIENLEYM peptide was
dded at a concentration of 3 3 1025 M to H-2b MC57
argets previously coated with 1025 to 10214 M viral
eptides and incubated with virus-specific effector CTLs.
s shown in Fig. 1, SMIENLEYM peptide effectively
locked killing by the known Db-restricted CTL clones to
CMV GP1, GP2, and NP. Previous studies using log
ilution of LCMV GP1, GP2, or NP peptides to coat target
ells (Hudrisier et al., 1996) showed that LCMV GP1
nd GP2 CTL clones were of lower affinity than NP
lones. These data were supported by experiments us-
ng different dilutions of antibodies to CD8 to block CTL
ysis. We confirmed and extended those data by showing
ere that 3 3 1025 M SMIENLEYM blocking peptide
borted GP1 CTL-mediated killing of target cells coated
ith 1025 M GP1 peptide and 1026 M GP2 peptide (Fig.
). However, when NP peptide was used at the same
oncentrations to coat targets SMIENLEYM peptide did
ot abort killing by the Db-restricted NP CTL clone. How-
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248 OLDSTONE ET AL.ver, the SMIENLEYM peptide was effective in aborting
P CTL-mediated lysis of targets coated with less NP
eptide (1029 M) (Fig. 1). Thus, the SMIENLEYM peptide
locked all three known kinds of Db-restricted CTLs that
ecognize the three immunodominant epitopes of LCMV.
urther, SMIENLEYM peptide successfully blocked Db-
estricted CTL lysis by CTLs generated to another RNA
irus, influenza, and to a DNA virus, SV40. As shown in
ig. 2, SMIENLEYM peptide prevented Db-restricted lysis
y an influenza CTL that recognized influenza NP aa
66–374 and by two independent SV40 clones that rec-
gnized T antigen aa 206–215 and aa 489–497, respec-
ively. These data indicated that a MHC allele-specific
ntagonist peptide could block CTLs generated to a
iverse number of different viruses.
MIENLEYM peptide blocks lysis of H-2b (Db) targets
y primary CTLs generated during an acute LCMV
nfection
We then tested the ability of SMIENLEYM to protect
CMV infected H-2b target cells from lysis by day 7
rimary H-2b-restricted LCMV splenic CTLs whose
ixed population of high-affinity CTLs would recognize
CMV GP1, GP2, and NP epitopes. As shown in Table 2,
MIENLEYM peptide at a concentration of 3 3 1025 M
T
Binding Affinity and CTL Activation Ability of Viral Peptides
Viruses aa sequence
Binding (Db)
IC50 (nM) Sou
. Good binders
LCMV CTL
GP1 aa 33–41 KAVYNFATC 48 6 10a V
GP2 aa 276–286 SGVENPGGYCL 13 6 3 7
2
NP aa 396–404 FQPQNGQFI 6 6 1 N
Prim
d
Influenza CTL
NP aa 366–374 ASNENMETM 26 6 4 L
SV40 CTL
T Ag aa 206–215 SAINNYAQKL 17 6 2 K
T Ag aa 489–497 QGINNLDNL 15 6 5 H
Blocking peptide SMIENLEYM 14 6 2 N
. Poor binders
LCMV Prim
GP aa 16–24 DEVINIVII .100,000 d
GP aa 321–329 LIDYNKAAL 1933 6 835 d
NP aa 45–53 SEVSNVQRI 1595 6 408 d
NP aa 372–381 GIDPNAPTWI .100,000 d
a Average value of at least three independent observations 6 stand
b N/A, not applicable. See Materials and Methods and Hudrisier etborted lysis of LCMV infected H-2b targets by day 7 arimary CTLs generated in H-2b (C57BL/6) mice but had
o effect on the killing activity of H-2d (Balb) day 7
rimary CTLs for H-2d targets. Further, when added to
ninfected H-2b targets, the SMIENLEYM peptide was
ot recognized by H-2b primary day 7 CTLs or CTL
lones, confirming that the designed peptide was not
ecognized by activated LCMV primed CTLs. Further, as
ig. 2 illustrates, specific blocking of lytic activity by H-2b
rimary CTLs was achieved when peptide was added in
he fluid phase or presented internally to the class I MHC
athway by use of a VV recombinant expressing a block-
ng peptide. In contrast, expression of H-2d NP peptide
a 118–127 using a VV promoter had no effect on block-
ng H-2b-restricted day 7 primary CTLs or H-2b-restricted
P1, GP2, and NP LCMV-specific CTL clones with re-
pect to the killing of LCMV infected H-2b targets. Hence,
he SMIENLEYM blocking peptide clearly aborted lysis in
itro by CTLs directed to all the known major (immuno-
ominant) Db-restricted LCMV CTL epitopes.
dministration of the SMIENLEYM Db blocking
eptide in vivo prevents immunopathologic disease
nduced by acute LCMV infection of H-2b mice
Figure 3 shows the result of giving 6- to 8-week old
-2b C57BL/6 mice 10 PFU of LCMV ARM ic alone or
ng the H-2Db Anchoring Motif for H-2Db MHC Molecules
CTLs
% Specific 51Cr Released from H-2b Targets
SMIENLEYM
blocking peptide
(1025 M) H-2d target
s Coated with
viral peptide
Coated with
SMIENLEYM
Coated with
viral peptide
7 44 6 4a 1 6 1 4 6 2
54 6 6 2 6 1 5 6 3
42 6 3 2 6 1 2 6 1
39 6 2 3 6 1 2 6 1
leen LCMV ARM
55 6 6 nil 3 6 2
s
54 6 3 4 6 2 3 6 2
s
, epi 30 6 3 5 6 3 2 6 1
i 26 6 2 2 6 1 4 6 2
N/A N/A 4 6 3
lenic LCMV ARM
4 6 2 N/A N/A
3 6 1 N/A N/A
2 6 1 N/A N/A
5 6 2 N/A N/A
or.
6) for details.ABLE 1
Beari
rce of
clone
V1-45-
7-82
28
P18
ary sp
7 CTL
clone
S NP
clone
-11-10
-1, ep
/Ab
ary sp
7 CTL
7 CTL
7 CTL
7 CTL
ard errlong with a nonblocking peptide (Fig. 3A). Within 8 days,
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249HIGH-AFFINITY PEPTIDE ABORTS MHC RESTRICTED CTL ACTIVITYll mice in these groups (24 mice per group) died. Anal-
sis of their brain tissue showed infiltrates of lympho-
ytes, both CD41 and CD81, in the leptomeninges and
entricles. Previously, in C57BL/6 mice whose CD81,
D41, MHC class I, MHC class II, perforin, or inter-
eron-g genes were individually disrupted, acute CNS
isease resulted solely from CD81 CTLs and perforin
Tishon et al., 1995; Kagi et al., 1994; Battegay et al., 1994;
atloubian et al., 1994). Similarly, the adoptive transfer of
FIG. 1. SMIENLEYM blocking peptide (solid bars) aborts lysis of H-2b
b-restricted LCMV-specific CTLs. MC57 (H-2b) 51Cr-labeled cells were
RM NP, GP1, and GP2 peptide from 1025 to 10214 M. Concurrently othe
f LCMV NP, GP1, or GP2 peptide only. Db-restricted CTL clones specif
dded at effector to target ratios of 5:1 and 2.5:1 with data for 5:1 sho
nd showed a variance of ,10% over the 5-h assay. See Materials and
ith LCMV.ndividual Db-restricted CTL clones specific for LCMV LRM GP1, GP2, or NP caused acute CNS death in im-
unosuppressed mice infected ic with LCMV (Joly et al.,
991).
Since SMIENLEYM peptide treatment successfully
locked lysis of LCMV infected targets by day 7 primary
TLs (Table 2) and these CTLs contained a population
hat recognized the three immunodominant LCMV ARM
eptide GP1, GP2, and NP CTL epitopes, we gave
MIENLEYM peptide (50 mg/dose, ic) with 10 PFU of
rgets sensitized to the three immunodominant LCMV CTL epitopes by
ted with 3 3 1025 M SMIENLEYM peptide and log dilutions of LCMV
(H-2b) 51Cr-labeled cells were incubated with 1025 to 10214 M dilutions
MV NP aa 396–404, LCMV GP1 aa 33–40, and GP2 aa 276–286 were
centage specific 51Cr release was calculated from triplicate samples
ds for details. These CTL clones did not recognize H-2d cells infected(Db) ta
incuba
r MC57
ic for LC
wn. Per
MethoCMV ARM. The LCMV-induced CD81 T-cell-mediated
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250 OLDSTONE ET AL.odel of CNS disease is a very stringent test of the
bility to block MHC-associated CTL killing by adoptive
ransfer studies, because fewer than 100 CTLs are re-
FIG. 2. SMIENLEYM blocking peptide (solid bars) aborts lysis of H-2b
Db) targets sensitized to influenza NP and SV40 T antigen specific CTL
pitopes by Db-restricted influenza and SV40 CTLs. MC57 (H-2b) 51Cr-
abeled cells were incubated with 3 3 1025 M SMIENLEYM peptide
nd log dilutions of influenza NP peptide ASNENMETM, SV40 T antigen
eptide SAINNYAQKL, or SV40 T antigen peptide QGINNLDNL at a
ange of 1025 to 1029 M. Concurrently other MC57 (H-2b) 51Cr-labeled
ells were incubated with 1025 to 1029 M dilutions of peptides of
nfluenza NP and the two SV40 T antigen CTL epitopes. Db-restricted
TL clones specific for influenza virus NP aa 366–374 and the two SV40
antigen peptides aa 206 to 215 and aa 489 to 497 were added at
ffector to target ratios of 5:1 and 2.5:1 with data for 5:1 shown.
ercentage specific 51Cr release was obtained from triplicate samples
hat showed a variance of ,10% over the 5-h assay. See Materials and
ethods for details. These CTL clones do not recognize H-2d cells
nfected with LCMV.uired to cause CNS death (Joly et al., 1991). Six of 24 or w5% of mice treated with the blocking peptide success-
ully resisted the universally fatal LCMV induced CTL-
ediated CNS disease. When surviving mice were sac-
ificed 30 days post ic inoculation their brains contained
ew infiltrating T cells (Fig. 3). No infectious virus was
ecovered from their brains, indicating that the LCMV
nfection had been controlled. Further, these survivors
ere immune to LCMV, since they resisted ic challenge
ith 10 PFU of the virus. These observations confirmed
ur earlier studies that when the Db allele is disrupted,
he Kb allele of H-2b can generate anti-LCM CTLs and
lear the viral infection (von Herrath et al., 1997).
In the second model of CD81 T-cell-mediated disease,
e used SMIENLEYM peptide to block insulin depen-
ent diabetes mellitus (IDDM) in transgenic mice in
hich the whole GP of LCMV ARM was expressed in
ancreatic b cells of the islets of Langerhans using the
IP, i.e., RIP-LCMV GP mice. In this model only perforin-
ependent CD81 T lymphocytes are involved in causing
DDM since CD41 CD82, CD81 perforin2, or b2g knock-
ut mice do not have this disease nor does it develop in
IP-LCMV GP mice until they are infected with LCMV
Oldstone et al., 1991; Laufer et al., 1993; Kagi et al., 1996).
hen SMIENLEYM peptide was given 1 week before or
t the time of LCMV challenge or 2 days after challenge,
o IDDM occurred as judged by testing for hyperglyce-
ia, hypoinsulinemia, or T cell infiltration, and destruc-
ion of b cells (Fig. 4) in over 95% of treated mice (10 mice
er group). The anti-LCMV precursor frequency was low-
red 24-fold from 1 in 250 to 1 per 6000 CD81 T cells. By
ontrast, in the absence of SMIENLEYM therapy, all 20
ice tested became diabetic.
DISCUSSION
Here we report the design of a peptide specific for a
HC class I allele that aborted virus-induced disease.
revious research has focused primarily on inhibiting the
inding of MHC class II molecules to exogenously pro-
essed antigens that, when bound, form complexes rec-
gnized by CD41 T lymphocytes (Guillet et al., 1986;
amont et al., 1990). However, physiologically, viruses
resent their peptides endogenously, and related tissue
njury is caused by CD81 lymphocytes. Here we used the
HC class I allele-specific blocking peptide SMIEN-
EYM, which competed with antigen presentation and
odified virus-mediated immunopathologic injury in vitro
nd in vivo. To reach this conclusion we evaluated mice
ith two distinct virus-induced CTL diseases. In one
roup, the agent of injury to pancreatic b cells was
ow-affinity (1028 M) antiviral CTL. The viral protein rec-
gnized was the GP1 and GP2 epitope located within the
CMV GP that is implanted and expressed in b cells by
sing RIP and transgenic technology. In adult transgenic
ice infected with LCMV, antiviral CTLs were generated
ith the same virus that served as a source of protein for
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251HIGH-AFFINITY PEPTIDE ABORTS MHC RESTRICTED CTL ACTIVITYmplantation into the b cells. That these CTLs caused the
isease process was confirmed when removal of CD8
von Herrath et al., 1994a) or MHC class I molecules
Laufer et al., 1993) prevented IDDM, whereas removal of
D4 (von Herrath et al., 1994) or B (Holz et al., 1997)
ymphocytes had no such effect. After H-2b (C57BL/6)
ice became acutely infected with LCMV, they routinely
enerated CTLs specific for GP aa 33–41, GP2 278–286,
nd NP aa 396–404. The GP CTLs ranged in affinity from
027 to 1028 M (moderate) as determined by varying the
ilutions of antigen to find those concentrations that
ctivated anti-LCMV CTLs and titering the amounts of
ntibody to CD8 required to block anti-LCMV CTL killing.
n contrast, results from the same assays proved that the
nti-LCMV NP CTLs had an affinity of 10213.5 or 5 to 6
ogs higher (Fig. 4; von Herrath et al., 1994b). Interest-
ngly, although the SMIENLEYM peptide blocked high-
ffinity NP CTLs in vitro, it only partially blocked IDDM in
ivo, presumably because sufficient concentrations of
eptide required are not reached. Thus in a transgenic
odel in which two viral peptide CTL epitopes are ex-
ressed, MHC class I allele-specific antagonist peptide
ompletely blocks disease initiated by low-affinity CTL
nd only partially aborts disease caused by high-affinity
TLs.
We then extended this model by determining whether
he blocking peptide was effective against high-affinity
TL by virtue of its interference of binding to all three
CMV Db restricted peptide epitopes. In this instance,
CMV inoculated ic into adult mouse brains and virus
T
SMIENLEYM Blocking Peptide (BP) Aborts
Mice CTL
source
E:T
ratio
H-2b Targets
LCMV
ARM V V/BPb
BP Peptid
1
LCMV AR
-2b d7 Po 50:1 39e 0 9
25:1 32 0 9
-2d d7 Po 50:1 3 0 2
25:1 2 0 1
-2b CTL clones
NP 5:1 63 0 8
GP1 5:1 80 0 2
GP2 5:1 56 0 2
a 5- to 6-h 51Cr release assay. Each sample was run in triplicate and
ethods for assay and for description of splenic CTLs and CTL clone
b VV/BP, vaccinia virus recombinant expressing SMIKNLEYM. Cells
c SMIENLEYM peptide added at a concentration of 3 3 1025 M.
d VV/H-2d, vaccinia recombinant expressing Ld-restricted peptide RP
e Mean value of triplicate samples. Variance ,10%.eplicated preferentially in cells lining the ventricles and heptomeninges (Borrow and Oldstone, 1997). In the
pleens and lymphnodes of the mice, high-affinity anti-
CMV CTLs to GP1, GP2, and NP CTL epitopes formed
apidly, trafficked through the blood, and entered the
rain where they sought the appropriate GP1, GP2, and
P peptides of LCMV restricted by Db MHC class I
olecules. The consequence was destruction of virally
nfected cells followed by cerebral edema and death in 6
o 8 days after inoculation. Again anti-LCMV-specific
D81 CTL played an exclusive role in this process as
hown when CNS disease did not develop in mice de-
leted of CD81 T cells (Tishon et al., 1995), perforin, or
HC class I expression (Borrow and Oldstone, 1997;
ishon et al., 1995; Kagi et al., 1994; Battegay et al., 1994;
atloubian et al., 1994). Complementation with LCMV-
pecific CTL clones to GP1, GP2, or NP by adoptive
ransfer into mice infected ic with LCMV but whose
ormal immune response had been suppressed led to
NS disease and death within 2 to 4 days (Joly et al.,
991). Similarly, CNS disease occurred in mice with a
D41, MHC class II, or B cell disruption (Borrow and
ldstone, 1997; Tishon et al., 1995; Holz et al., 1997).
gainst this background treatment with SMIENLEYM,
eptide saved 6 of 24 mice inoculated ic with LCMV. In
ontrast, a non-Db-blocking peptide failed to prevent the
NS disease, since all 24 mice died (Fig. 4). These
esults indicate that peptide treatment can be effective,
lbeit partially, even when high-affinity CTLs are gener-
ted to all the immunodominant peptide epitopes. While
n vivo therapy provided only partial protection against
of H-2b (Db) Targets Infected with LCMV
Specific 51Cr released froma
cells)
H-2d Targets (Balb/clone 7)
V V/BP 1
LCMV
ARM
V V/H-2d d
NP 1
LCMV
ARM
LCMV
ARM
BP
peptide
VV/H-2d
NP
0 34 0 2 4
0 18 0 4 1
0 ND 65 52 48
1 — 51 49 31
10 58 8 5 3
3 70 1 2 0
0 45 0 2 0
to target (E:T) ratios of 50:1, 25:1, or 1:1 were used. See Materials and
at m.o.i. of 10 overnight.
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254 OLDSTONE ET AL.otally abort high-affinity anti-LCMV CTL responses to all
hree known Db-restricted immunodominant peptide
pitopes, indicating that a system that delivers sufficient
mounts of blocking peptide to the potential disease site
n vivo may well achieve total protection against CTL-
ediated injury.
Interestingly, the blocking peptide designed and used
ere was effective against CTL responses not only to
CMV but also other viruses that mounted Db-restricted
TL responses. Accordingly, the blocking peptide pre-
ented lysis by high-affinity CTL clones to influenza virus
nd SV40 T antigen. Therefore the principles underlying
ur ability to block CTL recognition of a specific virus
hould extend to multiple viruses or self-antigens.
The CD81 immune response and likely other compo-
ents of the immune response to infectious agents is
ikely controlled both by a dominant MHC allele and by a
eries of immunodominant peptides. For H-2b mice, the
b allele appears dominant over the Kb allele during
CMV infection (Hudrisier et al., 1997; Lewicki et al.,
995a,b; von Herrath et al., 1997). However, when Db
ontrol was removed, Kb responses became evident and
ere sufficient to control viral infection (Lewicki et al.,
995b; von Herrath et al., 1997). For example, when Db
xpression was blocked in vivo by the E3 gene complex
f adenovirus expressed in b cells of the pancreatic
slets (von Herrath et al., 1997) or as shown here by Db
MIENLEYM treatment, infectious LCMV was, neverthe-
ess, cleared and persistent infection did not occur. The
3 adeno gene complex experiments are noteworthy in
hat they affect primarily Db but not Kb MHC class I
xpression (von Herrath et al., 1997). Although clearance
f virus by Kb-restricted LCMV-specific CTLs was effec-
ive it required several more days than Db-restricted
TLs to eliminate infectious virus. With other viruses,
HC domination of one allele over another has been
oted (Byrne et al., 1984; Mylin et al., 1995). In addition,
ontrol of immune responses occurs at the level of pro-
essing of viral peptides by the MHC class I molecule.
ven though only the three immunodominant CTL pep-
ide epitopes were apparent in H-2b mice following acute
CMV infection, mutation of these three epitopes or
epeated immunization allows the appearance of sub-
ominant epitopes (Lewicki et al., 1995a,b; van der Most
t al., 1998). These subdominant epitopes have the cor-
ect anchor and flanking sequences but are likely less
bundant or bind at lower affinity to the MHC class I
olecule inside the cell than their dominant counter-
arts. Nevertheless, when called upon the former can
ontrol acute virus infection and prevent persistence.
Finally, the design of MHC-specific, high-affinity pep-
ide inhibitors of class I MHC activity that themselves are
ot recognized by CTL can be achieved by determining
he requirements for MHC binding and CTL engagement
ith flanking aa as well as anchoring sequences of the
eptides. Here we analyzed endogenously processed migands of multiple viruses known to be good MHC bind-
rs and then used a computer program to obtain addi-
ional peptides that possessed the allele-specific motifs
n anchoring residues. Results from competitive blocking
ffinity assays enabled us to assign values to the various
atural flanking amino acids, thereby designating them
s good (,100 nmol IC50) or poor (.200 nmol IC50)
inders. By this means analog peptide could be gener-
ted with good stability, solubility, and ability to inhibit
HC class I antigen presentation. At present we are
etermining the minimal peptides required to achieve
HC class I-specific allele blocking, evaluating various
arriers to prolong peptide half-life in vivo, and planning
he possible synthesis of bio-organic compounds that
imic MHC class I allele binding peptides.
MATERIALS AND METHODS
ice, viruses, cell lines, and CTL clones
C57BL/6 (H-2bb) and Balb/ByJ (H-2dd) mice were ob-
ained from the breeding colony at The Scripps Research
nstitute. Mice used were 6 to 10 weeks of age. Viruses
sed were LCMV (ARM strain) clone 53b and recombi-
ant vaccinia viruses VV/H-2b GP (encoding full-length
CMV GP) and VV/BP (encoding a minigene correspond-
ng to a strong-binding Db “blocking peptide”). Viruses
ere quantified by plaque assay, and the recombinant
V was generated and used as described (Riviere et al.,
985; Whitton et al., 1988; Lewicki et al., 1995a,b; van der
ost et al., 1998; Hudrisier et al., 1996; Oldstone et al.,
991).
The MC57 (H-2bb), Balb Cl7 (H-2dd), and T2-Db cell
ines were maintained in continuous culture in the labo-
atory (Riviere et al., 1986; Whitton et al., 1988; Hudrisier
t al., 1996) and checked routinely to ensure that they
ere mycoplasma-free. All lines were maintained in
EM or RPMI medium supplemented with 7% fetal calf
erum, L-glutamine, and penicillin–streptomycin.
CTL clones were as follows: LCMV GP1 (VV1-45-7)
ecognizing LCMV GP aa 33–41 (KAVYNFATC), LCMV
P2 (77-82 or 228) recognizing LCMV GP aa 276–286
SGVENPGGYCL), and LCMV NP (NP 18) recognizing
CMV NP aa 396–404 (FQPQNGQFI); all these clones
ere H-2b (Db)-restricted (Lewicki et al., 1995a,b; Klavin-
kis et al., 1990; Oldstone et al., 1988; Yanagi et al., 1992).
LCMV NP clone (HD8) recognized LCMV NP aa 118–
27 and was H-2d (Ld)-restricted (Whitton et al., 1989). In
ddition we used an influenza NP clone (Vitiello et al.,
990) that recognized NP aa 366–374 (ASNENMETM)
eceived from Linda Sherman (The Scripps Research
nstitute, La Jolla). Two SV40 T antigen CTL clones (Lip-
olis et al., 1995; Mylin et al., 1995), K-11-10, epi that
ecognized SV40 aa 206–215 (SAINNYAQKL) and H-1, epi
hat recognized SV40 aa 489–497 (QGINNLDNL), were a
ift from Satvir Tevethia and Lawrence Mylin (Depart-
ent of Microbiology and Immunology, Pennsylvania
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255HIGH-AFFINITY PEPTIDE ABORTS MHC RESTRICTED CTL ACTIVITYtate College of Medicine, Hershey, PA). The influenza
nd SV40 CTL clones were H-2b (Db)-restricted. The
eneration, maintenance, specificity of recognition, and
se of these clones are detailed elsewhere (Lewicki et
l., 1995a,b; Klavinskis et al., 1990; Oldstone et al., 1988;
anagi et al., 1992; Whitton et al., 1989; Vitiello et al., 1990;
ippolis et al., 1995; Mylin et al., 1995).
eptides and binding studies
Peptides were synthesized on an automated peptide
ynthesizer (Applied Biosystems 430A) by the solid-
hase method using t-butoxyl or N-(9-fluorenyl)methoxy-
arbonyl (Fmoc) chemistry and then purified by high-
ressure liquid chromatography on a RP300-C8 re-
ersed-phase column and identified by fast atom
ombardment or electrospray mass spectrometry. The
-2Db-radioactive probe 125I-YAIENAEAL (sp act 40–80
B q/mmol) was prepared and purified as described
Hudrisier et al., 1996).
For the competitive binding assay, performed as de-
cribed (Hudrisier et al., 1996), T2-Db cells (1 3 105
ells/well) were incubated for 90 min at 37°C with 10 nM
25I-YAIENAEAL and increasing concentrations (10212 to
025 M) of unlabeled competitors. Cells were then
ashed three times with BSA–PBS, and the filters were
ounted for radioactivity. Total and nonspecific binding
as measured in the absence or presence of 1 mM
nlabeled YAIENAEAL. Specific binding to H-2Db was
efined as the difference between total and nonspecific
indings. IC50 represents the peptide concentration that
nhibited 50% of the specific binding of the radioactive
robe. Values are the mean 6 SE of at least three
ndependent experiments.
TL generation and detection
Primary LCMV-specific CTLs were generated by inoc-
lating mice intraperitoneally (ip) with 1 3 105 PFU of
CMV. Spleens from these mice were removed 7 days
fter inoculation, and single-cell suspensions of spleno-
ytes (free from erythrocytes) were prepared in complete
PMI 1640 medium as described (Riviere et al., 1986;
hitton et al., 1988; Oldstone et al., 1988, 1991; von
errath et al., 1994a,b; Lewicki et al., 1995a,b; Klavinskis
t al., 1990; Yanagi et al., 1992). These cells were then
ested for the ability to lyse virus infected or peptide
oated targets as described (Riviere et al., 1986; Whitton
t al., 1988; Oldstone et al., 1988, 1991; von Herrath et al.,
994; Lewicki et al., 1995; Klavinskis et al., 1990; Yanagi
t al., 1992). For in vitro blocking experiments, a constant
mount of blocking peptide (1025 M) was added with
olar dilutions of the specific CTL epitope peptide at
oncentrations ranging from 1025 to 10210 M.
A standard 5- to 6-h 51Cr release assay was used
Riviere et al., 1986; Whitton et al., 1988; Oldstone et al.,
988, 1991; von Herrath et al., 1994a,b; Lewicki et al., w995a,b; Klavinskis et al., 1990; Yanagi et al., 1992) to
easure CTL activity. Target cells were infected with
CMV ARM at an m.o.i. of 1, 48 h before the assay, or with
ecombinant VV at a m.o.i. of 3, 16 h before the assay.
ninfected cells were coated with peptides at various
ilutions immediately before the assay. Primary day 7
TLs were added at effector to target dilutions of 50:1,
5:1, and 12.5:1, whereas CTL clones were added at
ffector to target ratios of 5:1 and 2.5:1. The percentage
f specific lysis was calculated as 100 3 (CPM release
y CTL 2 CPM of spontaneous release)/(CPM of total
elease 2 CPM of spontaneous release).
n vivo immunopathology assays
Two in vivo assays were used (Borrow and Oldstone,
997; Oldstone et al., 1991; von Herrath et al., 1994a,b). In
he first, 6- to 8-week-old mice were inoculated ic with 10
FU of LCMV. Two groups of 24 mice each were used
ith one receiving 50 mg of LCMV GP1 peptide with the
iral inoculation, total volume 50 ml (control group), and
he other group a corresponding amount of blocking
eptide SMIENLEYM. Both peptides were administered
t the time of ic inoculation. Peptide injections in the
bsence of virus were repeated at days 2, 4, 6, and 8 past
he initial viral inoculation. Mice that were moribund,
sually at day 6 or 7 after infection, were sacrificed. Their
rains were removed and studied by light microscopy
nd immunohistochemistry for evidence of T lymphocyte
nfiltration and by plaquing for recovery of infectious
irus. SMIENLEYM peptide induces CTL responses to
tself after repeated inoculations. These CTLs are of low
ffinity and precursor numbers and are detectable only
fter in vitro stimulation in the presence of APCs coated
ith SMIENLEYM. The CTLs raised do not recognize
argets expressing LCMV antigens and do not recognize
urfaces of uninfected control target cells (see von
errath et al., 1998).
The second set of experiments utilized transgenic
ice that expressed the LCMV GP in b cells of the islets
f Langerhans in the pancreas using the rat insulin
romoter (RIP-LCMV GP mice). As described earlier,
uch transgenic mice have normal life spans with no
vidence of pancreatic disease until they are infected
ith LCMV ARM (Oldstone et al., 1991; von Herrath et al.,
994a). Two to five weeks after initiating infection, over
5% of such mice develop insulin-dependent diabetes as
udged by hyperglycemia, hypoinsulinemia in the pan-
reas, lymphocytic infiltration, and destruction of the is-
ets that uniformly leads to death. Such mice received
00 mg of blocking peptide SMIENLEYM daily over a
-week period (ip) after the initiation of an acute LCMV
nfection with 1 3 105 PFU given ip with repeated injec-
ions once a week for a total of 2 weeks. Blood glucose
as monitored as described (von Herrath et al., 1994a)
eekly, and diabetes-free mice were sacrificed 3 to 6
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256 OLDSTONE ET AL.onths after initiation of infection. Their pancreatic tis-
ues were then studied immunochemically for expres-
ion of insulin in b cells and CD4, CD8 lymphocytes
nfiltrating islets (Oldstone et al., 1991; von Herrath et al.,
994a). Similar immunochemical analysis was performed
n pancreas obtained from three mice from each group
t 14 days after LCMV infection was initiated.
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